CLOs on the Move

Indivior

www.indivior.com

 
The world leader in addiction treatment with over 20 years of experience and a patient-focused approach. We didn`t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They`re often unaware of their treatment options, have limited access to treatment, or simply don`t seek it out because they`re afraid of being stigmatized. Since our inception, we have actively partnered with healthcare professionals, the public health community, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.indivior.com
  • 10710 Midlothian Turnpike Suite 430
    Richmond, VA USA 23235
  • Phone: 804.379.1090

Executives

Name Title Contact Details
Stephen Kim
General Counsel, Commercial Profile
Randy Batenhorst
Senior Vice President - Regulatory Affairs Profile
Jessica Colon
VP, Deputy Compliance Officer Profile
Javier Rodriguez
Chief Legal Officer Profile
Javier Rodriguez
Chief Legal Officer Profile

Similar Companies

Leesville Rehabilitation Hospital

Leesville Rehabilitation Hospital is a Leesville, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vibalogics

Vibalogics is a CDMO offering process development, manufacturing, testing, and fill-finish services to innovators developing revolutionary virotherapy products.

Aja Labs

Superhuman hair. Engineered from nature.

Stealth BioTherapeutics

Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.

Ontera

Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.